Table 3 |
|||||
| Evaluation for PAS and association with immunoreactivity for p63, α-SMA, E-cadherin and Ki-67 in groups | |||||
| Score | Areas | ||||
| In situ | Invasive | ||||
| Group 1 | Group 2 | Group 1 | Group 2 | ||
| p63 | 0 | 0/20 | 1/21 | 12/21 | 13/21 |
| 1 | 0/20 | 3/21 | 6/21 | 5/21 | |
| 2 | 7/20 | 6/21 | 3/21 | 3/21 | |
| 3 | 13/20 | 11/21 | 0/21 | 0/21 | |
| α-SMA | 0 | 1/20 | 6/21 | 13/21 | 14/21 |
| 1 | 5/20 | 5/21 | 8/21 | 6/21 | |
| 2 | 4/20 | 3/21 | 0/21 | 1/21 | |
| 3 | 10/20 | 7/21 | 0/21 | 0/21 | |
| E-cadherin | 0 | 0/24 | 0/24 | 17/25 | 15/24 |
| 1 | 3/24 | 7/24 | 8/25 | 9/24 | |
| 2 | 21/24 | 17/24 | 0/25 | 0/24 | |
| Ki-67 (Mean value) | 5.6 (22) | 8.7 (22) | 5.62 (22) | 12 (22) | |
Group 1, represented by cases with low versican expression; and Group 2, represented by cases with versican overexpression.
Significant differences at P < 0.0001 between in situ and invasive areas in p63, α-SMA, and e-cadherin using the Wilcoxon Test.
Damasceno et al. BMC Veterinary Research 2012 8:195 doi:10.1186/1746-6148-8-195
